This fall

USADA published a guide to MOTS-c — and classified it as banned in sport

USADA published guidance on MOTS-c this fall, classifying it explicitly as a prohibited substance under the World Anti-Doping Agency's Prohibited List. The classification sits in Section S4.4 as a metabolic modulator and AMPK activator, banned at all times — meaning in-competition and out. Therapeutic use exemptions are not available because there is no approved therapeutic use. [USADA's MOTS-c guidance](https://www.usada.org/spirit-of-sport/what-is-mots-c-peptide/) describes the ban in plain language any drug-tested athlete should read before touching a gray-market vial with any version of the name on it. The timing is worth noting. A Phase 2a randomized, double-blind, placebo-controlled trial of MOTS-c is currently registered on ClinicalTrials.gov — the first rigorous human efficacy test of the peptide — with primary endpoints around insulin sensitivity in adults with prediabetes. That trial is enrolling now. No results have posted. The WADA ban and the first human trial are running in parallel in September 2026. A substance can be both regulated and understudied at the same time, and MOTS-c is currently both.

The actual molecule

MOTS-c is encoded by mitochondrial DNA and was only identified a decade ago

MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA-c — a name that tells you the most unusual thing about it. MOTS-c is not encoded by nuclear DNA. It is encoded by mitochondrial DNA, specifically within the 12S ribosomal RNA gene. That discovery came from Changhan David Lee's lab at USC in 2015, which identified functional peptides hiding inside the mitochondrial genome at a time when it was assumed that mitochondrial DNA produced only the structural components of the respiratory chain. The biological rationale for the interest is AMPK activation. MOTS-c appears to function as a cellular energy sensor: in animal models it rises during exercise and caloric restriction, activates AMP-activated protein kinase — the same pathway engaged by metformin, the world's most widely prescribed diabetes drug — and appears to shift how cells handle glucose and lipids under metabolic stress. [PubMed indexes several hundred MOTS-c publications](https://pubmed.ncbi.nlm.nih.gov/?term=MOTS-c), the majority in preclinical models, reflecting genuine scientific interest in a mechanism that could matter for metabolism, exercise biology, and aging.

The wellness claim

the exercise mimetic story runs louder than the evidence it's built on

The public story about MOTS-c runs in two lanes. The longevity lane sells it as an exercise mimetic — a molecule that activates the metabolic benefits of physical exercise without requiring the exercise. The athlete lane treats it as a performance and recovery enhancer, which is partly why WADA noticed it. Neither version spends much time on the fact that MOTS-c is a peptide your cells already produce endogenously, and that administering an exogenous version at doses and schedules your body has never encountered in controlled human studies is a meaningfully different intervention than anything observational research can tell you. The gray-market supply ecosystem has grown around the concept anyway. Research chemical sellers list MOTS-c vials openly, and in September 2026, at least one supplier issued a press release announcing documentation and traceability updates for its MOTS-c reference material — an institutional-sounding move that tracks a broader pattern of unregulated sellers attempting to appear more legitimate amid intensifying FDA enforcement attention. The substance described in those announcements remains experimental and unapproved for any human use.

What the data shows

the preclinical story is real — but no completed human RCT has posted results

The September 2026 evidence file for MOTS-c has three parts. First, a genuine preclinical literature that is growing in scope. A 2025 paper in Experimental & Molecular Medicine showed MOTS-c preventing pancreatic islet cell senescence in mouse models — the most recent addition to a research direction that includes metabolic, exercise, and aging-biology angles. [Nature, 2025](https://www.nature.com/articles/s12276-025-01521-1). Second, the 2021 CohBar Phase 1b study — the only prior human exposure data — which tested CB4211, a MOTS-c analog, in 20 adults with elevated liver fat for 28 days. It was a safety and dose-finding study, not an efficacy test, and reported no serious adverse events. Twenty participants for 28 days is a narrow human footprint. Third, the Phase 2a trial now registered on [ClinicalTrials.gov](https://clinicaltrials.gov/search?term=MOTS-c): randomized, double-blind, placebo-controlled, enrolling adults with prediabetes and overweight, testing insulin sensitivity changes at 16 weeks. That trial has not posted results. The preclinical biology is sufficient to justify running it. It is not sufficient to justify the certainty the gray-market pricing already reflects.

Animal / preclinical — PeptideFactCheck stance

the WADA ban and the Phase 2 trial are two readings of the same gap

MOTS-c holds Animal / preclinical here because the completed evidence is preclinical. USADA is explicit that no completed human clinical trials exist, and the CohBar Phase 1b in 20 people is a safety observation, not the efficacy literature the longevity market has priced in. WADA's decision to add MOTS-c to the Prohibited List before Phase 2 results exist reflects anti-doping's precautionary logic: the AMPK mechanism is sufficiently performance-relevant that the agency is not waiting. That may or may not be proportionate to the actual risk the experimental peptide presents — that is a legitimate debate. It does not change what the evidence says. The FDA's PCAC also reviewed MOTS-c in July 2026 as part of the wave that included BPC-157 and other compounding-adjacent peptides, and [FDA's bulk compounding safety page](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) is the relevant frame for where that stands. Animal / preclinical is the evidence reality in September 2026. The Phase 2a trial will either change that tier or confirm it. Source trail before certainty — and on MOTS-c, the trail has not yet posted its most important data.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.